Add to ORKGPurpose We designed a phase I/II trial of intraperitoneal (IP) docetaxel plus S-1 to determine the maximum toler-ated dose (MTD) and recommended dose (RD) and to evaluate its efficacy and safety in gastric cancer patients with peritoneal carcinomatosis (PC). Methods Patients with PC confirmed by laparoscopy or laparotomy received IP docetaxel on days 1 and 15 and S-1 (80 mg/m2) on days 1–14 every 4 weeks. Results In the phase I part (n = 12), each cohort received escalating doses of docetaxel (35–50 mg/m2); the MTD was determined to be 50 mg/m2 and the RD was deter-mined to be 45 mg/m2. Dose-limiting toxicities included grade 3 febrile neutropenia and grade 3 diarrhea. In the phase II part (n = 27), the median number of courses was 4 (range...
Background: We conducted a phase I trial to determine the safety and maximum tolerated dose (MTD) of...
Background: Benefits of chemotherapy have generally been modest in gastric cancer, although those re...
Background. Cytoreductive surgery (CRS) and intraperi-toneal chemotherapy (IPC) is an established th...
Background: Docetaxel plus cisplatin (DP) is a combination chemotherapy regimen that is active again...
BACKGROUND: Patients with gastric cancer and peritoneal carcinomatosis have a very poor prognosis; m...
Owing to its peculiar pharmacological characteristics, paclitaxel attains substantial intra-per-iton...
Background: Docetaxel is a new agent with activity in metastatic gastric cancer. This phase II study...
Objective: S-1 and cisplatin combination therapy is a standard regimen for patients with advanced ga...
PURPOSE: The incidence of adenocarcinoma of the lower third of the esophagus, esophagogastric juncti...
Copyright © 2014 Giulia Montori et al.This is an open access article distributed under the Creative ...
OBJECTIVES: Docetaxel is an inhibitor of microtubule depolymerization and has demonstrated activity ...
Background. Peritoneal carcinomatosis (PC) is an unmet medical need. Despite recent improvements, sy...
PURPOSE: To evaluate intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies that...
Background: Intraperitoneal administration of paclitaxel (PTX) can elicit a marked clinical response...
Objective: Owing to the risks of serious and sustained toxicity, anticancer drugs such as cis-platin...
Background: We conducted a phase I trial to determine the safety and maximum tolerated dose (MTD) of...
Background: Benefits of chemotherapy have generally been modest in gastric cancer, although those re...
Background. Cytoreductive surgery (CRS) and intraperi-toneal chemotherapy (IPC) is an established th...
Background: Docetaxel plus cisplatin (DP) is a combination chemotherapy regimen that is active again...
BACKGROUND: Patients with gastric cancer and peritoneal carcinomatosis have a very poor prognosis; m...
Owing to its peculiar pharmacological characteristics, paclitaxel attains substantial intra-per-iton...
Background: Docetaxel is a new agent with activity in metastatic gastric cancer. This phase II study...
Objective: S-1 and cisplatin combination therapy is a standard regimen for patients with advanced ga...
PURPOSE: The incidence of adenocarcinoma of the lower third of the esophagus, esophagogastric juncti...
Copyright © 2014 Giulia Montori et al.This is an open access article distributed under the Creative ...
OBJECTIVES: Docetaxel is an inhibitor of microtubule depolymerization and has demonstrated activity ...
Background. Peritoneal carcinomatosis (PC) is an unmet medical need. Despite recent improvements, sy...
PURPOSE: To evaluate intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies that...
Background: Intraperitoneal administration of paclitaxel (PTX) can elicit a marked clinical response...
Objective: Owing to the risks of serious and sustained toxicity, anticancer drugs such as cis-platin...
Background: We conducted a phase I trial to determine the safety and maximum tolerated dose (MTD) of...
Background: Benefits of chemotherapy have generally been modest in gastric cancer, although those re...
Background. Cytoreductive surgery (CRS) and intraperi-toneal chemotherapy (IPC) is an established th...